Benchmark Holdings has announced its unaudited interim H1 and Q2 results based on strong FY21 performance. The company also showed its unaudited results in compliance with the terms of its senior secured bond.
Regarding this, CEO Trond Williksen said: "Benchmark delivered strong double-digit revenue growth across all our business areas. A doubling of adjusted EBITDA, and a significant increase in adjusted EBITDA margin. Q2 represented the fourth consecutive quarter of substantial growth in the group's revenues and adjusted EBITDA."
As operating highlights, the company mentioned good progress on the roll-out of Ectosan® Vet and CleanTreat®. Also, continued strong momentum in advanced nutrition, and growth in salmon egg sales in Genetics. Besides, the commercialization of specific pathogen-resistant (SPR) shrimp progressing well with good take-up in key markets including India. Furthermore, an investment in solar panels in Thailand which will contribute significantly toward Net Zero targets
Finally, Williksen concluded: "We have visible growth opportunities underpinned by existing infrastructure and are uniquely positioned in an industry with strong fundamentals driven by megatrends."
